Disease · MONDO_0005366

chronic hepatitis B virus infection

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. chronic hepatitis B virus infection. Diseases, record MONDO_0005366. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005366

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: chronic hepatitis B virus infection; Open Targets
Open Targets ID: MONDO_0005366; Open Targets
Other names: CHB, chronic Hepatitis B, chronic hepatitis B infection, hepatitis B infection, chronic, hepatitis B, chronic; Open Targets
MeSH: D019694; MeSH
Highest stage of its drugs: Approval, for 9 of its 82 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA and PMDA; Open Targets

Drugs82

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ENTECAVIR	CHEMBL5314362	Small molecule	Approval	DailyMed, EMA Human Drugs and PMDA	97	88	86	Drugs and targets
PEGINTERFERON ALFA-2A	CHEMBL1201560	Protein	Approval	EMA Human Drugs	75	74	68	Drugs and targets
TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Small molecule	Approval	DailyMed and PMDA	58	52	49	Drugs and targets
TELBIVUDINE	CHEMBL374731	Small molecule	Approval	FDA	29	27	27	Drugs and targets
ADEFOVIR DIPIVOXIL	CHEMBL922	Small molecule	Approval	ClinicalTrials.gov, DailyMed and PMDA	27	22	19	Drugs and targets
LAMIVUDINE	CHEMBL141	Small molecule	Approval	DailyMed, EMA Human Drugs and PMDA	30	17	17	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Approval	FDA	16	13	6	Drugs and targets
TENOFOVIR ALAFENAMIDE FUMARATE	CHEMBL2364637	Small molecule	Approval	DailyMed	7	6	6	Drugs and targets
TENOFOVIR DISOPROXIL	CHEMBL1538	Small molecule	Approval	EMA Human Drugs	6	5	5	Drugs and targets
PEGINTERFERON ALFA-2B	CHEMBL1201561	Protein	Phase 3	ClinicalTrials.gov	21	21	12	Drugs and targets

1 to 10 of 82

See all 82 drugs

Targets55

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IFNAR1	Interferon alpha/beta receptor	6	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Approval	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	6	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Approval	https://conductscience.org/library/genes/3455	Drugs and targets
KDR	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	3	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
BRAF	Serine/threonine-protein kinase B-raf	2	Serine/threonine-protein kinase B-raf inhibitor	Phase 2	https://conductscience.org/library/genes/673	Drugs and targets
CD274	Programmed cell death 1 ligand 1	2	Programmed cell death 1 ligand 1 inhibitor	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	2	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets

1 to 10 of 55

See all 55 targets

Trials283

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 9 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01329419	HEPSERA Post Marketing Surveillance		4,393	2011-04-05	Hepatitis B	ADEFOVIR DIPIVOXIL	Its record names the disease	ClinicalTrials.gov
NCT00142298	Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies	Phase 3	1,869	2011-07-25	Chronic Hepatitis B	TELBIVUDINE	Its record names the disease	ClinicalTrials.gov
NCT01855997	A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue		1,669	2016-04-08	Hepatitis B, Chronic	PEGINTERFERON ALFA-2A	Its record names the disease	ClinicalTrials.gov
NCT01277601	Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B	Phase 4	751	2015-09-09	Chronic Hepatitis B	PEGINTERFERON ALFA-2A, TENOFOVIR DISOPROXIL FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT00536263	PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)	Phase 3	671	2010-12-21	Hepatitis B, Chronic	PEGINTERFERON ALFA-2B	Its record names the disease	ClinicalTrials.gov
NCT00410202	Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus	Phase 3	629	2012-07-04	Hepatitis B, Chronic	ADEFOVIR, ENTECAVIR	Its record names the disease	ClinicalTrials.gov
NCT00435825	A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).	Phase 4	551	2013-06-25	Hepatitis B, Chronic	PEGINTERFERON ALFA-2A	Its record names the disease	ClinicalTrials.gov
NCT00324961	Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B	Phase 4	533	2009-10-02	Chronic Hepatitis B	ADEFOVIR DIPIVOXIL	Its record names the disease	ClinicalTrials.gov
NCT01300234	Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)	Phase 3	512	2013-08-16	Hepatitis B	ADEFOVIR DIPIVOXIL, TENOFOVIR DISOPROXIL FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT03982186	A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection	Phase 2	471	2024-07-10	Hepatitis B, Chronic	BERSACAPAVIR	Its record names the disease	ClinicalTrials.gov

1 to 10 of 283

See all 283 trials

Comparisons in its trials64

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
TDF-TDF vs ADV-TDF: deaths from any cause	1 of 257	0 of 252	509	NCT01300234	Trial comparisons
TDF-TDF vs ADV-TDF: serious adverse events	12 of 257	20 of 252	509	NCT01300234	Trial comparisons
Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Serious Adverse Events	11 of 102	7 of 99	201	NCT01369212	Trial comparisons
Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Adverse Events	50 of 102	60 of 99	201	NCT01369212	Trial comparisons
Tenofovir vs Peginterferon-alfa 2a and Tenofovir: deaths from any cause	0 of 102	0 of 99	201	NCT01369212	Trial comparisons
Tenofovir vs Peginterferon-alfa 2a and Tenofovir: serious adverse events	11 of 102	7 of 99	201	NCT01369212	Trial comparisons
Peginterferon Alfa-2a + Entecavir vs Entecavir: serious adverse events	6 of 97	0 of 100	197	NCT00940485	Trial comparisons
Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBsAg Seroconversion at Week 192	1 of 96	4 of 92	188	NCT01369212	Trial comparisons
Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Alanine Transaminase(ALT) Levels <= 38 U/L for Males and <=25 for Females at Week 192	58 of 96	72 of 91	187	NCT01369212	Trial comparisons
Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Normal Alanine Transaminase (ALT) Levels at Week 192	37 of 96	51 of 91	187	NCT01369212	Trial comparisons

1 to 10 of 64

See all 64 comparisons in its trials

Papers from its trials213

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35870702	RESULT	1	PubMed
35216027	RESULT	1	PubMed
35090390	RESULT	1	PubMed
34731856	RESULT	1	PubMed
33465271	RESULT	1	PubMed
33404182	RESULT	1	PubMed
32304611	RESULT	1	PubMed
32282538	RESULT	1	PubMed
32102898	RESULT	1	PubMed
31994737	RESULT	1	PubMed

1 to 10 of 213

See all 213 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005366

GET https://conductscience.org/api/diseases/v1/MONDO_0005366/drugs?page=2

API reference For AI assistants